Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy
JournalItem (Reviews, Editorials, Rezensionen, Urteilsanmerkungen etc. in einer wissenschaftlichen Zeitschrift)
 
ID 1197105
Author(s) Bitzer, Johannes; Kenemans, Peter; Mueck, Alfred O; FSDeducation Group
Author(s) at UniBasel Bitzer, Johannes
Year 2008
Title Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy
Journal Maturitas
Volume 59
Number 3
Pages 209-18
Keywords postmenopausal patients, exogenous testosterone, oestrogen/testosterone combination therapy, breast cancer risk, review
Abstract OBJECTIVES: Testosterone supplementation can be considered as a treatment option for surgically postmenopausal women with a distressful low sexual desire disorder, while on oestrogen therapy with or without progestagens. The purpose of this study is to review the available clinical data on the impact of exogenous testosterone containing postmenopausal hormone therapy on breast cancer risk. METHODS: A literature search was done in MEDLINE (1969-July 2007) and in addition in EMBASE and Biosis (1990-July 2007) for original reports in English and French. Case reports and studies without a control group were excluded. RESULTS: No prospective randomized clinical trials were found. The five studies found (two case-control studies, two cohort studies and one retrospective observational study) showed inconsistent results. All studies had severe methodological limitations. Formulations and dosages used could be considered suboptimal. CONCLUSION: At present, there are no valid randomized or observational clinical studies that provide evidence that the addition of testosterone to conventional postmenopausal hormone therapy influences breast cancer risk.
Publisher ELSEVIER IRELAND LTD
ISSN/ISBN 0378-5122
edoc-URL http://edoc.unibas.ch/dok/A6007262
Full Text on edoc No
Digital Object Identifier DOI 10.1016/j.maturitas.2008.01.005
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/18343056
ISI-Number WOS:000256110500001
Document type (ISI) Journal Article, Review
 
   

MCSS v5.8 PRO. 0.350 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
30/04/2024